

Table of Contents

Allan Vaag, Professor - Lund University and Steno Diabetes Center Copenhagen	2
Angus Jones, Associate Professor - Exeter University	2
Chantal Mathieu, Professor - Katholieke Universiteit Leuven.....	3
Christian Collin, living with type 1.5 diabetes - Steno Diabetes Center Copenhagen	3
Coen D.A. Stehouwer, Professor - Maastricht University.....	4
Ebba Carbonnier, Portfolio Manager, Director Quantum Life Science - Swelife and Karolinska Institutet	4
Elizabeth Selvin, Professor - Johns Hopkins University	5
Gary Frost, Professor - Imperial College London.....	5
Guillaume Paré, Professor - McMaster University	6
Haifa Maalmi, Dr. - German Diabetes Center	6
Isabel Goncalves, Professor - Lund University	7
Juleen R. Zierath, Professor - Karolinska Institute and University of Copenhagen.....	7
Jørgen Wojtaszewski, Professor - University of Copenhagen	8
K. M. Venkat Narayan, Professor - Emory University	8
Maria Tørnes, Nurse Specialist - Steno Diabetes Center Zealand.....	9
Martin Ridderstråle, Senior Vice President - Novo Nordisk Foundation	9
John J. Nolan, Adjunct Professor - Trinity College Dublin	10
Paul W. Franks, Scientific Director, Professor - Novo Nordisk Foundation	10
Robert Wagner, Professor - Heinrich Heine University Düsseldorf	11
Ronald C.W. Ma, Professor - Chinese University of Hong Kong.....	11
Ruth Loos, Professor - University of Copenhagen and Icahn School of Medicine at Mount Sinai	12
Shivani Misra, Dr. - Imperial College London.....	12
Sophie Hindkjær, living with type 1 diabetes - Steno Diabetes Center Copenhagen.....	13
Stefano Del Prato, Professor - University of Pisa	13
Thusius Rajeeth Savarimuthu, Professor - University of Southern Denmark.....	14
Tina Vilsbøll, Professor - Steno Diabetes Center Copenhagen	14
Torben Hansen, Professor - University of Copenhagen	15
William T. Cefalu, Dr. - National Institute of Diabetes and Digestive and Kidney Diseases	15

Allan Vaag, Professor

- Lund University and Steno Diabetes Center Copenhagen

Allan Vaag is Professor of Endocrinology (Chair) at Lunds University, Sweden, and Consultant at the Department of Endocrinology, Skåne University Hospital, Malmö, Sweden. Furthermore, he is an Affiliated Professor of Translational Type 2 Diabetes Research at the Department of Biomedical Sciences, University of Copenhagen (DK), as well as Consultant (20% position) at Steno Diabetes Center Copenhagen (DK). He has been awarded Gold Medal Oration and Distinguished Scientist Award (IN) in 2010, Knud Lundbæk Prisen (DK) in 2012, and Hede Nielsen Prisen (DK) in 2015.

He graduated with an MD from the University of Southern Denmark in 1986, and subsequently defended his Ph.D. as well as Doctor of Medical Science (DMSc) degrees from the same university in 1993 and 1999, respectively. He is a board certified specialist in internal medicine and endocrinology, and his translational research has for more than three decades had its key focus on the pathophysiology of type 2 diabetes (T2D). Allan Vaag special interests include precision medicine and subphenotyping of T2D, as well as understanding the molecular mechanisms linking the exposure to an adverse fetal environment with increased risk of developing T2D.

Angus Jones, Associate Professor

- Exeter University

Angus Jones is an Associate Professor at the University of Exeter, and an Honorary Consultant Physician at the Royal Devon and Exeter Hospital. He trained in medicine in London and completed his Ph.D. with Professor Andrew Hattersley in Exeter, studying the clinical utility of C-peptide testing in diabetes management.

His research interests are in precision approaches to the management of diabetes, with a focus on practical approaches that can impact clinical practice now or in the near future. This includes approaches to improving the clinical classification of diabetes, both through optimizing the use of classification biomarkers such as C-peptide and islet autoantibodies and through the development of prediction models to combine clinical features and biomarkers to guide diabetes classification and treatment. This work has informed national and international guidance in this area. Additional interests include developing stratified approaches to the treatment of type 2 diabetes, and, as part of his work with the University of Exeter NIHR Global Health Group, approaches to effective diabetes diagnosis, monitoring, and classification in low resource settings. He has previously been awarded UK National Institute of Health Research (NIHR) Doctoral and Clinician Scientist fellowships and a Rising Star award from the European Association for the Study of Diabetes.

Chantal Mathieu, Professor

- Katholieke Universiteit Leuven

Chantal Mathieu is a Professor of Medicine at KU Leuven (BE) and Chair of Endocrinology at University Hospital Gasthuisberg Leuven. Furthermore, she is the Senior Vice President of the European Association for Study of Diabetes and Chair of the European Diabetes Forum. Professor Mathieu coordinates the INNODIA project on biomarkers and arrest of type 1 diabetes and has served on several boards.

She graduated with an MD from the University of Leuven in 1988 and obtained her Ph.D. from the University of Leuven. She is trained in internal medicine and endocrinology. Professor Mathieu's research is focused on the prevention of type 1 diabetes, the effects of vitamin D on the immune system and diabetes, and the functioning of the insulin-producing beta cell. She is involved in several clinical trials in type 1 and 2 diabetes.

Christian Collin, living with type 1.5 diabetes

- Steno Diabetes Center Copenhagen

Christian Collin is a chief pilot in the Danish aviation industry as well as a flight instructor and examiner. Furthermore, Christian Collin is a partner in MA&P, a consulting company in the aviation and healthcare sector that provides management systems, analysis, support, and advisory based on experience in the operational environment of commercial aviation.

Christian Collin was in 2017 diagnosed with diabetes type 1.5, a subtype of type 1 diabetes also known as LADA. He is a user of the Steno Diabetes Center Copenhagen, which offers world-class treatment for diabetes in Denmark. In 2019, he became a member of the Steno Diabetes Center Copenhagen's Board of Directors as a user representative. This initiative intensifies the focus on user involvement which aims to strengthen the Center in decision-making and development processes. Christian Collin contributes with the user perspective on different topics ranging from research to economics and the construction of new facilities. His focus as a board member is especially on the mental aspects of living with diabetes and how the diagnosis can change the patient's life dramatically. Therefore, he aims to create more opportunities for diabetic patients to share knowledge and exchange experiences with each other but also to ensure that working environments and regulations follow the development of diabetes technology and insulins.

Coen D.A. Stehouwer, Professor

- Maastricht University

Coen D. A. Stehouwer, MD, is a professor of Internal Medicine and Chair of the Department of Internal Medicine at Maastricht University (NL). Furthermore, he is the principal investigator of the Maastricht Study. Professor Stehouwer has received numerous awards for his pivotal role in diabetes research, including the Donald McDonald Award of Artery Society (2017), the Dutch Society of Vascular Medicine Career Award (2007) and the Camillo Golgi Prize (EASD, 2005).

He graduated with an MD from Erasmus University in Rotterdam in 1985 (NL) and obtained his Ph.D. from Vrije Universiteit (NL) in 1992. He was trained in epidemiology and molecular biology and is now a clinician-scientist. In his research, Professor Stehouwer fuses epidemiology, clinical physiology, and experiments to get a better understanding of metabolic changes in (pre)diabetes as well as micro- and macrovascular diseases, and to elucidate non-classical complications of diabetes, including cognitive dysfunction, and late-life depression.

Ebba Carbonnier, Portfolio Manager, Director Quantum Life Science

- Swelife and Karolinska Institutet

Ebba Carbonnier is a Portfolio Manager at Swelife (S), a Strategic Innovation Programme within Life Science. Examples of some of the national projects within the portfolio are; Genomic Medicine Sweden Data, Cell- and Gene Therapy, Prevention of childhood obesity and Quantum Life Science projects. On a more long-term strategic level, the aim is to gradually focus more on keeping our population healthy from a Healthy-Risk-Sick perspective. A large proportion of national budgets and projects are focusing on the Sick-part, but from a system perspective, it is more advantageous to invest in the Healthy part, to do it right from the start. We only spend three percent on prediction and prevention (OECD), although we can prevent 80% of heart and cardiovascular diseases and type 2 diabetes.

Carbonnier also serves as Director for a newly initiated National Quantum Life Science Centre at Karolinska Institutet.

Prior to Swelife and KI, Carbonnier has 14 years of Management Consulting experience, ranging from daily management of teams to creating and implementing strategies for global companies. Managing large scale multinational projects at e.g. AstraZeneca, Microsoft and Sandvik, is an area where Carbonnier has extensive experience. Carbonnier holds an MSc and an MBA with a focus on Operations Management.

Elizabeth Selvin, Professor

- Johns Hopkins University

Elizabeth Selvin is a Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health (US). She holds a joint appointment in General Internal Medicine in the Johns Hopkins School of Medicine. She is the author or co-author of over 500 papers in the peer-reviewed literature including landmark papers in the New England Journal of Medicine, JAMA, The Lancet, Annals of Internal Medicine, Diabetes Care, Circulation, and other major medical journals. In 2013, she was awarded the Harry Keen Memorial Award by the International Diabetes Epidemiology Group of the International Diabetes Federation and she was the 2020 winner of the Kelly M. West Award for Outstanding Achievement in Epidemiology from the American Diabetes Association.

She graduated with a Master of Public Health from the University of Michigan (US) in 2001 and obtained her Ph.D. from Johns Hopkins Bloomberg School of Public Health in 2004. Professor Selvin focuses on translational research, public health policy, and clinical practices in diabetes. She evaluates and improves screening, diagnosis, and patient care, and her work has led to changes in clinical guidelines regarding the diagnosis and management of diabetes. Her research is centered around biomarkers and diagnostics related to diabetes and its implications.

Gary Frost, Professor

- Imperial College London

Gary Frost is a Professor of Nutrition and Dietetics at Imperial College London (UK). He graduated with a BSc in Nutrition from Leeds University, whereupon he qualified as a dietician in 1982 and obtained a Ph.D. in Nutrition and Dietetics from the University of London. In 2005 he joined as a professor at the University of Surrey, subsequently at Imperial College London.

Professor Frost has over 30 years of clinical dietetics and nutrition research experience. His research group have a wide interest in the relationship between food and metabolism. A major focus of the group is the metabolism of dietary carbohydrates and their role in appetite regulation, insulin resistance, and lipid metabolism. In particular, the glycemic index as a model of the physiological effects of carbohydrates and the metabolic effect of products of carbohydrate fermentation. He has been investigating obesity management with a focus on the basic nutritional physiology involved in energy balance.

In recent years in partnership with Prof Holmes and Drs Garcia Perez and Posma he has developed metabolomic based techniques to assess diet and individual response to food. This team has in the recent years been applying this research within the start-up company Melico Sciences.

Guillaume Paré, Professor

- McMaster University

Guillaume Paré holds several positions at McMaster (CA), including Professor of Pathology and Molecular Medicine at the Faculty of Health Sciences, University Scholar, Director of the Medical Biochemistry Postgraduate Education program, Director of the Population Genomics Program, and Co-Director of McMaster Genome Facility. He graduated with an MD from the University of Montreal (CA) in 2002, followed by an MSc in Human Genetics from McGill University (CA) in 2006. He obtained the title of Medical Biochemist at the University of Montreal in 2007 and in 2009 he became a research fellow at Harvard Medical School, where he was trained in genetic epidemiology.

Professor Paré's research focuses on Genetic and Molecular Epidemiology, where he aims to identify genetic determinants of complex diseases such as lipoprotein disorders, obesity, and cardiovascular disease. His research originates from the belief that genetic and molecular markers of disease are expected to lead to a better understanding, prediction, and ultimately prevention of diseases, including a focus on pharmacogenomics.

Haifa Maalmi, Dr.

- German Diabetes Center

Dr. Haifa Maalmi is a senior epidemiologist at the German Diabetes Center in Duesseldorf. Her re-search focuses on discovering and validating serum protein biomarkers associated with diabetes-related complications. Besides biomarkers discovery, she uses epidemiological methods and relevant observational studies to characterise the heterogeneity of diabetes subtypes (differences in proteo-mic profiles and risk of complications) as a step towards advancing precision medicine in diabetes.

Dr. Maalmi received her PhD in epidemiology in 2019 from the University of Heidelberg, Germany. Before that, she received a PhD in biology in 2014 from the University of Tunis El Manar, followed by research stays in scientific institutions in Germany (German Cancer Research Center), France (University of Nantes) and Qatar (Weill Cornell Medicine). For her work on diabetes, she has been awarded research grants from the German Center for Diabetes Research (DZD), the German Diabetes Association (DDG) and the runner-up award of the 2022 EFSD/Novo Nordisk Foundation Diabetes Precision Medicine Award Programme. Currently, she serves as a member of the editorial board of "Diabetes Metabolism Research and Reviews".

Isabel Goncalves, Professor

- Lund University

Isabel Goncalves holds several positions at Lund University (S), including being Professor of Cardiology at the Faculty of Medicine, Research team manager at Cardiovascular Research, Principal investigator at EXODIAB; a national strategic research area in diabetes and researcher at EpiHealth; Epidemiology for Health. Previously, she was vice-chair and member of the RÅG for Life-sciences of the Swedish Research Council for infrastructures, Now Swedish Research Council for medicine cardiovascular and respiratory systems. Professor Goncalves has been awarded several prizes, including the prize of Best Young Scientist from the Swedish Medical Association in 2012 and a big grant of SEK 15 million (€1,38) from the Heart and Lung Foundation in 2014, awarded by Prince Daniel.

She graduated with an MD from Lisbon University in 1999, AT 2001, has worked in Heidelberg, Germany, Karolinska Stockholm, and obtained a Ph.D. in 2002 at Lund University. Professor Goncalves has a special focus on atherosclerotic plaques, covering mechanisms of development and techniques for imaging. Currently, it is impossible to detect which patients have rupture-prone plaques being at risk for heart attacks, strokes, and sudden death. She aims to improve this and find novel and timely treatment avenues for those subjects.

Juleen R. Zierath, Professor

- Karolinska Institute and University of Copenhagen

Juleen R. Zierath is a Professor of Clinical Integrative Physiology at Karolinska Institutet, Stockholm (S), and Professor and Executive Director at the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen (DK). She is a member of the Nobel Assembly and Nobel Committee for Physiology or Medicine, the Royal Swedish Academy of Science, the European Molecular Biology Organization, and Academia Europaea. She former Chair of the Nobel Committee and President of the European Association for the Study of Diabetes (EASD). She has received several awards, including the Claude Bernard Medal and Minkowski Prize from the EASD, the Harold Rifkin Award for Distinguished international Service in the Cause of Diabetes from ADA, and a Distinguished Alumnus Award and Honorary Doctorate of Science from University of Wisconsin-River Falls.

She graduated with an M.A. in Exercise Physiology from Ball State University (US) in 1986 and Ph.D. in Medical Science from Karolinska Institutet in 1995. She performs translational research to delineate mechanisms for Type 2 diabetes pathogenesis. Current work is focused on the role of epigenetic processes for insulin resistance and the interaction between circadian rhythms and exercise training in the control of metabolism.

Jørgen Wojtaszewski, Professor

- University of Copenhagen

Jørgen Frank Pind Wojtaszewski (JW) is professor at Department of Nutrition Exercise and Sports, University of Copenhagen (UCPH), and is heading The August Krogh Section for Molecular Physiology. JW achieved his MSc in Human Physiology (1992) and in Human Biology (1994) from UCPH. In 1997 JW was awarded the degree of PhD in Natural Science. JW received 8 years of post doctoral training through research conducted at the August Krogh Institute (UCPH), at the Copenhagen Muscle Research Center (UCPH) and at Joslin Diabetes Center, Harvard University, Boston US. JW has served as professor in Molecular Physiology since 2008 at UCPH. JW is heading the August Krogh Club, serve as Named Person at UCPH and is member of the educational board at Danish Diabetes Academy.

Our research focus on the mechanism(s) by which physical activity promotes metabolic health. Of particular interest is the interaction at the intracellular level between exercise-induced signaling events and those induced by insulin trying to elucidate the mechanisms by which a single bout of exercise improves muscle insulin sensitivity. Our approaches to gain such insights include invasive studies of healthy and diseased subjects in combination with mechanistic studies using transgenic animal models and state of art omics technologies. In collaborations with clinical laboratories and pharma industries, we aim to translate our findings into relevance for patients and society.

K. M. Venkat Narayan, Professor

- Emory University

K.M. Venkat Narayan, MD, MSc, MBA is Executive Director of the Emory Global Diabetes Research Center, and Ruth and OC Hubert Chair of Global Health at Emory University. He is a Professor of Global Health and Epidemiology at Emory Rollins School of Public Health, and Professor of Endocrinology at Emory School of Medicine. He is a member of the US National Academy of Medicine and his awards include the American Diabetes Association's Kelly West Award for Outstanding Achievement in Epidemiology, and Danish Diabetes Academy Visiting Professorship.

He was formerly head of the diabetes science branch at the Centers for Disease Control and Prevention (CDC), and intramural researcher at the National Institutes of Health (NIH). Professor Narayan has led and/or collaborated with in several major national and international multi-center epidemiological studies (Pima, CARRS, SEARCH, TRIAD), randomized controlled trials (DPP, ACCORD, CARRS), and more. He is currently principal investigator for Precision-CARRS (a 22,000 people cohort of South Asians), and is exploring pancreatic

beta cell biology and intriguing differences in the pathophysiology of type 2 diabetes in Asian, Africa, Native American, and developing countries' populations globally.

Maria Tørnes, Nurse Specialist

- Steno Diabetes Center Zealand

Maria Tørnes is a Nurse Specialist in diabetes, at Steno Diabetes Center Zealand (DK). She has several years of experience in both the public health care system and the industry. She graduated from Herlev Nursing School in 2004. Afterward, she worked as a project and diabetes nurse at Steno Diabetes Center Zealand. She has been working with big studies as LEADER and CASCADE. Followed by a position at Novo Nordisk as Clinical Safety Associate, before becoming a diabetes nurse at the Center for Diabetes. Maria has also worked for the Danish Diabetes association with education of children and their families in her early career.

In her daily work, she has a special focus on transition in patients with type 1 diabetes and is part of a working group in that. She also has a focus on diabetes stress, not only in type 1 diabetes. Diabetes is a very interesting field, therefore also interests in many other things.

Privately Maria is married to Uffe. Uffe is working as Senior Director of Commercial Supply Chain at Genmab. Together they have two daughters Cathrine (2012) and Vilma (2016). Cathrine has type 1 diabetes and has had it since she was 3 years old (since 2015). Diabetes in childhood is also a focus Maria has, but in a more private context.

Martin Ridderstråle, Senior Vice President

- Novo Nordisk Foundation

Martin Ridderstråle is Chief Medical Officer and Senior Vice President of Medical Science, an area that supports research and development from basic discoveries across to clinical care through broad open calls in competition overseen by the Committees for Basic Biomedicine, Endocrinology and Metabolism, Clinical and Translational Medicine and Nursing Research, respectively, to strategic initiatives such as the Novo Nordisk Foundation Center for Basic Metabolic Research, the Novo Nordisk Foundation reNEW Stem Cell Center, and the seven Steno Diabetes Centers.

Martin Ridderstråle is an MD, specialist in Internal Medicine, Endocrinology and Diabetology, and has a Ph.D. in Molecular Signaling from Lund University in Sweden, where he has also been Adjunct Professor of Endocrinology, and an MBA from Copenhagen Business School. Martin Ridderstråle has worked as Head of the Department of Endocrinology and Deputy Head of the Division of Specialised Medicine at Skåne University Hospital in Sweden, and Vice President and Head of Clinic at Steno Diabetes Center in Gentofte. Before

joining the Novo Nordisk Foundation, he was working as Corporate Vice President of Clinical Pharmacology and Translational Medicine at Novo Nordisk A/S.

John J. Nolan, Adjunct Professor

- Trinity College Dublin

John Nolan is an Adjunct Professor of Endocrinology and Metabolism and an honorary Fellow at Trinity College Dublin (IE). He has a clinical appointment as consultant endocrinologist at Wexford General Hospital. From 2011-2016 John Nolan was CEO and Head of the Steno Diabetes Center in Copenhagen (DK). From 2017-19 he was Chief Scientific Officer of the European Association for the Study of Diabetes and led the development of the new European Diabetes Forum, officially launched in 2020. He is an Executive member of the ADA/EASD Precision Medicine in Diabetes Initiative (2018-present).

He graduated from University College Dublin in Biochemistry (BSc, 1978) and then in Medicine (MB, BCh, 1985). He pursued postgraduate training in Internal Medicine in Ireland, followed by a fellowship in Endocrinology and Metabolism and first faculty appointment at the University of California, San Diego. His research has centered on the pathophysiology of Type 2 diabetes, including the mechanisms underlying the prevention of Type 2 diabetes. His current focus is translational medicine with a particular interest in the development of precision medicine for diabetes.

Paul W. Franks, Scientific Director, Professor

- Novo Nordisk Foundation

Paul Franks is the head of Translational Medicine at the Novo Nordisk Foundation. He has served on many advisory panels and expert groups including those of MRC, NIH, and WHO, and on the editorial boards of several journals including *Diabetologia*, *Hypertension*, *BMC Medical Genomics*, and *Obesity*. He currently chairs the ADA/EASD Precision Medicine in Diabetes Initiative. He was previously the Vice-President Elect of the Nordic Society of Human Genetics and Precision Medicine and the chair of the Genomic Medicine Sweden Complex Trait Initiative.

In 2003 he obtained a Ph.D. in Genetic Epidemiology from the Institute of Public Health, University of Cambridge (UK). In 2010, he was appointed Professor of Genetic Epidemiology at Lund University (S) and Adjunct Professor at the Harvard School of Public Health (US). He was deputy director of Lund University Diabetes Centre from 2016-2021.

Robert Wagner, Professor

- Heinrich Heine University Düsseldorf

Robert Wagner is a professor of Clinical Research in Diabetes and Metabolic Diseases at Heinrich Heine University Düsseldorf (DE) and Deputy Department Lead at the Department of Endocrinology and Diabetology at the University Hospital Düsseldorf. Additionally, he is Head of Clinical Research Center at German Diabetes Center, Leibniz Center for Diabetes Research. In 2021 he won the Ferdinand-Bertram-Prize from the German Diabetes Association and the Prevention Prize from the German Society of Internal Medicine.

He graduated as an MD from Semmelweis University (HU) in 2003, but prior to this degree, he obtained a Master of Management Information Systems in 2000. He was trained in Internal Medicine and Endocrinology and has 12 years of experience in clinical studies. His main interest is understanding the main pathogenetic drivers of type 2 diabetes by disentangling the heterogeneity of the disease. He has a special focus on bioinformatic tools in the understanding of beta cell dysfunction. He takes part in both design, coordination, and realization of multiple clinical studies.

Ronald C.W. Ma, Professor

- Chinese University of Hong Kong

Ronald Ma is a Professor and Head of the Division of Endocrinology and Diabetes, Department of Medicine and Therapeutics, as well as Assistant Dean of Faculty of Medicine at the Chinese University of Hong Kong (CN). Professor Ma is the Co-director of the Chinese University of Hong Kong – Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine and on the Steering Committee of the Hong Kong Institute of Diabetes and Obesity. He has contributed to the understanding of diabetes in Asians and is the principal investigator of the newly established Hong Kong Diabetes Biobank. Professor Ma plays an active role in diabetes advocacy as former President of the International Diabetes Epidemiology Group (IDEG) and has served in several other organizations and Boards, including the Asian Association for the Study of Diabetes (AASD).

He obtained his medical qualification from Cambridge University (UK) in 1994 and was trained in Internal Medicine in London. He subsequently returned to Hong Kong, where he completed his endocrinology fellowship training, followed by a research fellowship at the Joslin Diabetes Center, Harvard Medical School. Professor Ma's research interests include the epidemiology and genetics of diabetes and its complications, gestational diabetes, and the developmental origins of diabetes.

Ruth Loos, Professor

- University of Copenhagen and Icahn School of Medicine at Mount Sinai

Ruth Loos is the Vice Executive Director and Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (DK). Furthermore, she is the Director of the Genetics of Obesity and Related Metabolic Traits Program and Professor of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai (US). She graduated with an MSc in Kinesiology and Exercise Science from the University of Leuven (BE) in 1993 and obtained her Ph.D. in 2001.

Her research focuses on the etiology of obesity and the identification of genes and genetic loci contributing to the risk of obesity and related traits. By identifying genes, she aims to gain insight into the biology that underlies body weight regulation and the mechanisms that link adiposity to its comorbidities. Furthermore, she studies more refined adiposity phenotypes and biomarkers to target the deeper layers that define “obesity”. Besides gene discovery, she uses epidemiological methods to assess the role of genetic information in precision medicine of common obesity by examining its value in identifying subtypes of obesity, predicting who is at risk of gaining weight, and in tailoring prevention and treatment strategies.

Shivani Misra, Dr.

- Imperial College London

Shivani Misra is a Wellcome Trust Career Development Clinician Scientist at Imperial College London and an Honorary Consultant Physician in Metabolic Medicine at Imperial College Healthcare NHS Trust.

Her Wellcome-Trust funded research is centered around the genetics and epidemiology of early-onset type 2 diabetes, which disproportionately affects people from Asian and African-Caribbean ethnicities. Her projects aim to define the heterogeneity of early-onset type 2 diabetes and how this can be leveraged to improve patient outcomes. She is a co-investigator on an NIHR programme grant assessing interventions for young adults with type 2 diabetes and she also specialises in atypical forms of diabetes, studying the classification of diabetes subtypes across diverse ancestries.

She undertook her Ph.D. at Imperial College London in 2017 and was lead investigator of the MY DIABETES study, recruiting and stratifying UK Asian and African-Caribbean individuals with early-onset diabetes using biomarkers, to identify monogenic diabetes. Her work across diverse ancestries earned her a Future Leaders Mentorship Award from the European Federation for the Study of Diabetes in 2017 and she currently serves as Co-Chair of the ADA consensus working group on precision diagnostics in type 2 diabetes.

Sophie Hindkjær, living with type 1 diabetes

- Steno Diabetes Center Copenhagen

Sophie Hindkjær was diagnosed with type 1 diabetes 11 years ago and sits on the board of the Danish Diabetes Association and Steno Diabetes Center Copenhagen. Sophie is working within law at the Danish Prison and Probation Services, and lives with her husband and their wonderful toddler.

Sophie's involvement in the diabetes community spans from being a volunteer at the Danish Diabetes Association, working with #Dedoc, the international diabetes federation Europe (IDF Europe), and Team Novo Nordisk to running a youth initiative, Cafe Suk, with the aim of giving teens and their parents' peer-to-peer support and diabetes "role models". One of Sophie's main focuses within diabetes, is that no one should feel that they are alone with their disease. This is because her greatest resource of up-to-date knowledge on diabetes treatments is from her friends and peers within the diabetes community.

Stefano Del Prato, Professor

- University of Pisa

Stefano Del Prato, MD, is a Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa, and Chief of the Section of Diabetes, University Hospital of Pisa (I). He is President of the EASD and the EFSD, past President and Honorary President of the Italian Society of Diabetology, and a member of many other societies and associations including the American Diabetes Association. He acts as a referee for numerous journals and has served on the Editorial Boards of major scientific journals in the field of diabetes and metabolism. Professor Del Prato has published over 500 articles in national and international journals. He has been awarded several honors including the Prize of the Italian Society of Diabetology for outstanding scientific activity, the Order of Merit of the Italian Republic and the Honorary Professorship at the Universidad Peruana Cayetano Heredia in Lima.

He graduated with an MD from the University of Padova (I) and undertook a postgraduate specialization in Endocrinology and Internal Medicine. He has been an Associate Professor of Medicine at the University of Texas, San Antonio, TX (US). His main research interests have always been the physiopathology and therapy of type 2 diabetes and insulin resistance.

Thiusius Rajeeth Savarimuthu, Professor

- University of Southern Denmark

Thiusius Rajeeth Savarimuthu is a Professor of Medical Robotics at The Mærsk Mc-Kinney Møller Institute at the University of Southern Denmark (DK) and Deputy Head of SDU Robotics. Furthermore, he is an R/D Consultant on Surgical applications using Robots at Odense University Hospital (DK). He has been honored with a series of prizes, including the Innovation Prize rewarded by the University of Southern Denmark in 2020.

He graduated with an M.Sc.Eng in Computer System Engineering from the University of Southern Denmark in 2007. He obtained a Ph.D. in Robotics from the University of Southern Denmark in 2011. Professor Savarimuthu's research interests include industrial robotics, hardware acceleration of image processing algorithms, and control of medical robotics systems. He has been worked alongside doctors his whole career to help them optimize medical procedures with robotics. In addition to this, Professor Savarimuthu helped to develop a corona swap robot during the pandemic.

Tina Vilsbøll, Professor

- Steno Diabetes Center Copenhagen

Tina Vilsbøll a consultant at Steno Diabetes Center Copenhagen (DK), and a Professor at the University of Copenhagen. Professor Vilsbøll has been involved in clinical research since 1997, and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark now part of Steno Diabetes Center Copenhagen.

She graduated with an MD from University of Copenhagen, Denmark in 1995 and defended her doctoral thesis (DMsc) in 2003. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes, monogenetic diabetes, regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus for her over recent years. Professor Vilsbøll is an experienced teacher and supervises several Ph.D. and medical students conducting diabetes research. She has more than 390 scientific publications (H-index 75), several published books, and book chapters. She is a frequently invited speaker at international meetings. In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals.

Torben Hansen, Professor

- University of Copenhagen

Torben Hansen is a Professor of Molecular Metabolism and Director of the Programme Human Genomics and Metagenomics in Metabolism and the Hansen Group, Genomic Physiology and Translation at the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen (DK). He is also involved in pre- and postgraduate educational activities at the Universities of Copenhagen, Aarhus, and Odense. Since 2005, he has collaborated with Steno Diabetes Center in Copenhagen on molecular genetic diagnostics of monogenic forms of diabetes and obesity.

He graduated with an MD from the University of Copenhagen in 1984 and obtained his Ph.D. from the University of Copenhagen in 1992. His major research interests are the pathophysiology and pathogenesis of type 2 diabetes, obesity, and metabolic syndrome, and the identification of genetic determinants for both mono and polygenic components of diabetes and obesity. Furthermore, his recent research is also focused on the impact of the gut and saliva microbiome on disease and health and the crosstalk between the host genome and the microbiome.

William T. Cefalu, Dr.

- National Institute of Diabetes and Digestive and Kidney Diseases

William T. Cefalu is the Director of the Division of Diabetes, Endocrinology, and Metabolic Diseases, at National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) (US). From 2013 to 2017, he was Executive Director, Pennington Biomedical Research Center, Louisiana State University (LSU) from 2015 to 2017, he held the George A. Bray, Jr. Endowed Super Chair in Nutrition. In 2017, he joined the American Diabetes Association as Chief Scientific, Medical and Mission Officer. From 2011-2017 he served as editor-in-chief of Diabetes Care.

He graduated with an MD from LSU Health Sciences Center, New Orleans in 1979. He was trained in endocrinology and metabolism at University of California Los Angeles (UCLA). In his research, he focused on interventions to improve the metabolic state of individuals with insulin resistance and type 2 diabetes. He has been the principal investigator for two NIH funded research centers. In his current position at NIDDK since 2019, he oversees a division that outlines new scientific initiatives and funds investigation into basic, clinical, and translational research for type 1 and type 2 diabetes.